Cited by 573Angiogenesis and VEGF in CancerColorectal Cancer Treatments and StudiesBreast Cancer Treatment Studies

The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.

Biomarkers of response and resistance to antiangiogenic therapy

Open access

Jain, Rakesh K., Duda, Dan G., Willett, Christopher G., Sahani, Dushyant V., Zhu, Andrew X., Loeffler, Jay S., Batchelor, Tracy T., Sorensen, A. Gregory·2009·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2009.63PMC PMC3057433

Open this paper in CoChat — free account

Abstract

No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2009.63

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citation
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citation
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622

Flagged first, then by citations

Show all 83 references

1 of the 83 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 573

Liquid biopsies in patients with diffuse glioma
Best, M. G., Sol, N., Zijl, S., Reijneveld, J. C., Wesseling, P., & Würdinger, T. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1399-y · Cited by 94
C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells
Hiratsuka, S., Duda, D. G., Huang, Y., Goel, S., Sugiyama, T., Nagasawa, T., Fukumura, D., & Jain, R. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016917108 · Cited by 94
Self-citation
Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer
Nazari, A., Khorramdelazad, H., & Hassanshahi, G. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1187-x · Cited by 91
Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma
Favier, J., Igaz, P., Burnichon, N., Amar, L., Libé, R., Badoual, C., Tissier, F., Bertherat, J. Y., Plouin, P., Jeunemaı̂tre, X., et al. (2011) · Endocrine Pathology · doi:10.1007/s12022-011-9189-0 · Cited by 86
Failures in Phase III: Causes and Consequences
Šeruga, B., Ocaña, A., Amir, E., & Tannock, I. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0124 · Cited by 93
The angiogenic process as a therapeutic target in cancer
Bridges, E., & Harris, A. L. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.02.016 · Cited by 87
Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
Tang, P. A., Cohen, S. J., Kollmannsberger, C., Bjarnason, G. A., Virik, K., MacKenzie, M. J., Lourenço, L., Wang, L. E., Chen, A. P., & Moore, M. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3252 · Cited by 88
Novel Oncologic Drugs: What They Do and How They Affect Images
Figueiras, R. G., Padhani, A. R., Goh, V., Vilanova, J. C., González, S. B., Martín, C. V., Gómez‐Caamaño, A., Naveira, A. B., & Choyke, P. L. (2011) · Radiographics · doi:10.1148/rg.317115108 · Cited by 85
Obesity and Cancer Metastasis: Molecular and Translational Perspectives
Annett, S., Moore, G., & Robson, T. (2020) · Cancers · doi:10.3390/cancers12123798 · Cited by 93
Optimizing the Delivery of Cancer Drugs That Block Angiogenesis
Cao, Y., & Langer, R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000399 · Cited by 86
Stanniocalcin-1 and -2 promote angiogenic sprouting in HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways
Law, A. Y. S., & Wong, C. K. C. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.04.024 · Cited by 86
Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas
Yoon, S. S., Duda, D. G., Karl, D. L., Kim, T., Kambadakone, A. R., Chen, Y., Rothrock, C., Rosenberg, A. E., Nielsen, G. P., Kirsch, D. G., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.024 · Cited by 82
Self-citation
Tumor-Surrogate Blood Vessel Subtypes Exhibit Differential Susceptibility to Anti-VEGF Therapy
Sitohy, B., Nagy, J. A., Jaminet, S.-C. S., & Dvorak, H. F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1693 · Cited by 82
Placental growth factor in cancer
Dewerchin, M. A., & Carmeliet, P. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.948420 · Cited by 82
Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC
Peng, F.-W., Ji, X., Wu, T.-T., Xue, J., Ren, Z., Liu, D., Wang, X., Chen, X.-H., Zhang, J., Xu, Y., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.033 · Cited by 81
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial
Schmitz-Winnenthal, F. H., Hohmann, N., Niethammer, A. G., Friedrich, T., Lubenau, H., Springer, M., Breiner, K. M., Mikus, G., Weitz, J., Ulrich, A. B., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1001217 · Cited by 77
Antiangiogenic effect of licochalcone A
Kim, Y. H., Shin, E. K., Kim, D. H., Lee, H. H., Park, J. H. Y., & Kim, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.006 · Cited by 77
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma
Goyal, L., Zheng, H., Abrams, T. A., Miksad, R. A., Bullock, A. J., Allen, J. N., Yurgelun, M. B. B., Clark, J. W., Kambadakone, A. R., Muzikansky, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0847 · Cited by 76
Self-citation
Tumors vs. Chronic Wounds: An Immune Cell's Perspective
Hua, Y., & Bergers, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02178 · Cited by 82
Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies
Grépin, R., & Pagès, G. (2010) · Journal of Oncology · doi:10.1155/2010/835680 · Cited by 76
Targeting angiogenesis in head and neck cancer
Vassilakopoulou, M., Psyrri, A. K., & Argiris, A. E. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.01.006 · Cited by 78
Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab
Ellingson, B. M., Cloughesy, T. F., Lai, A., Mischel, P. S., Nghiemphu, P. L., Lalezari, S., Schmainda, K. M., & Pope, W. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor079 · Cited by 75
Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment
Lee, E., Pandey, N. B., & Popel, A. S. (2015) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.2 · Cited by 75
Targeting the VEGF signaling pathway in cancer therapy
Waldner, M. J., & Neurath, M. F. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.641951 · Cited by 74
Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Zhu, A. X., Ancukiewicz, M., Supko, J. G., Sahani, D. V., Blaszkowsky, L. S., Meyerhardt, J. A., Abrams, T. A., McCleary, N. J., Bhargava, P., Muzikansky, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3041 · Cited by 75
Self-citation
Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse
Arevalo, O., Soto, C., Rabiei, P., Kamali, A., Ballester, L. Y., Esquenazi, Y., Zhu, J., & Riascos, R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00460 · Cited by 74
MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients
Gámez‐Pozo, A., Antón-Aparicio, L. M., Bayona, C., Borrega, P., Sancho, M. I. G., García-Domínguez, R., de Portugal, T., Ramos-Vázquez, M., Pérez-Carrión, R., Bolós, M. V., et al. (2012) · Neoplasia · doi:10.1593/neo.12734 · Cited by 72
Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective
Verheij, M., Vens, C., & van Triest, B. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.01.002 · Cited by 71
Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization
Nardo, G., Favaro, E., Curtarello, M., Moserle, L., Zulato, E., Persano, L., Rossi, E. M. C., Esposito, G., Crescenzi, M., Casanovas, O., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0242 · Cited by 75
Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
Loupakis, F., Cremolini, C., Yang, D., Salvatore, L., Zhang, W., Wakatsuki, T., Bohanes, P. O., Schirripa, M., Benhaïm, L., Lonardi, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066774 · Cited by 71
Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor β1
LI, G.-C., ZHANG, H.-W., ZHAO, Q.-C., SUN, L., YANG, J.-J., HONG, L., FENG, F., & CAI, L. (2016) · Oncology Letters · doi:10.3892/ol.2015.3997 · Cited by 72
A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers
Ribba, B., Watkin, E., Tod, M. M., Girard, P., Grenier, E., You, B., Giraudo, E., & Freyer, G. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.003 · Cited by 70
Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors
Taraboletti, G., Rusnati, M., Ragona, L., & Colombo, G. (2010) · Oncotarget · doi:10.18632/oncotarget.200 · Cited by 70
Obesity and Cancer: An Angiogenic and Inflammatory Link
Fukumura, D., Incio, J., Shankaraiah, R. C., & Jain, R. K. (2016) · Microcirculation · doi:10.1111/micc.12270 · Cited by 69
Self-citation
Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
Moreno, V., Basu, B., Molife, L. R., & Kaye, S. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1275 · Cited by 70
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
Dragovich, T., Laheru, D. A., Dayyani, F., Bolejack, V., Smith, L., Seng, J., Burris, H. A., Rosen, P. J., Hidalgo, M. M., Ritch, P. S., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2499-4 · Cited by 69
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 70
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives
Shen, Y., Hsu, C., & Cheng, A. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0270-0 · Cited by 71
Simultaneous determination of labile proton concentration and exchange rate utilizing optimal RF power: Radio frequency power (RFP) dependence of chemical exchange saturation transfer (CEST) MRI
Sun, P. Z. (2009) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2009.10.012 · Cited by 68
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.
Dey, N., De, P. K. R., & Leyland-Jones, B. (2015) · Europe PMC (PubMed Central) · Cited by 68
Antiangiogenesis therapy: an update after the first decade
Falco, S. D. (2014) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2014.29.1.1 · Cited by 72
Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma
Alberts, S. R., Fitch, T. R., Kim, G. P., Morlan, B. W., Dakhil, S. R., Gross, H. M., & Nair, S. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182118cdf · Cited by 67
Adaptive response of resistant cancer cells to chemotherapy
Chern, Y., & Tai, I. T. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0005 · Cited by 67
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
Eatock, M. M., Tebbutt, N. C., Bampton, C. L., Strickland, A. H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.-N., Zhong, Z. D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds502 · Cited by 64
Neutrophils expressing lysyl oxidase‐like 4 protein are present in colorectal cancer liver metastases resistant to anti‐angiogenic therapy
Palmieri, V., Lazaris, A., Mayer, T. Z., Petrillo, S. K., Alamri, H., Rada, M., Jarrouj, G., Park, W., Gao, Z., McDonald, P. P., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5449 · Cited by 64
VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy
Greenberg, J. I., & Cheresh, D. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903208883 · Cited by 66
Mechanism of hypertension and proteinuria during angiogenesis inhibition
Lankhorst, S., Kappers, M. H. W., van Esch, J. H. M., Danser, A. H. J., & van den Meiracker, A. H. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835c1d1b · Cited by 65
Multiscale Imaging and Computational Modeling of Blood Flow in the Tumor Vasculature
Kim, E., Stamatelos, S. K., Cebulla, J., Bhujwalla, Z. M., Popel, A. S., & Pathak, A. P. (2012) · Annals of Biomedical Engineering · doi:10.1007/s10439-012-0585-5 · Cited by 63
Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor
Crocker, M., Ashley, S. E., Giddings, I., Petrik, V., Hardcastle, A., Aherne, W., Pearson, A., Bell, B. A., Zacharoulis, S., & Papadopoulos, M. C. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq170 · Cited by 63
Monitoring of tumor vascular normalization: the key points from basic research to clinical application
Li, W., Quan, Y., Li, Y., Lu, L., & Cui, M. (2018) · Cancer Management and Research · doi:10.2147/cmar.s174712 · Cited by 62
Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis
Eswarappa, S. M., & Fox, P. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3805 · Cited by 62
Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
Brauer, M. J., Zhuang, G., Schmidt, M., Yao, J. J., Wu, X., Kaminker, J. S., Jurinka, S. S., Kolumam, G. A., Chung, A. S., Jubb, A. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3635 · Cited by 64
Targeted nanoparticles in imaging: paving the way for personalized medicine in the battle against cancer
Shin, S. J., Beech, J., & Kelly, K. A. (2012) · Integrative Biology · doi:10.1039/c2ib20047c · Cited by 61
Genetics of Glioblastoma: A Window into Its Imaging and Histopathologic Variability
Belden, C. J., Valdes, P. A., Ran, C., Pastel, D. A., Harris, B. T., Fadul, C. E., Israel, M. A., Paulsen, K. D., & Roberts, D. W. (2011) · Radiographics · doi:10.1148/rg.316115512 · Cited by 60
Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine
Alsaab, H. O., Al-Hibs, A. S., Alzhrani, R. M., Alrabighi, K. K., Alqathama, A. A., Alwithenani, A., Almalki, A. H., & Althobaiti, Y. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041631 · Cited by 62
The Role of Functional Imaging in Colorectal Cancer
Figueiras, R. G., Goh, V., Padhani, A. R., Naveira, A. B., Gómez‐Caamaño, A., & Martin, C. V. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.10.4422 · Cited by 60
Vessel calibre—a potential MRI biomarker of tumour response in clinical trials
Emblem, K. E., Farrar, C. T., Gerstner, E. R., Batchelor, T. T., Borra, R., Rosen, B. R., Sorensen, A. G., & Jain, R. K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.126 · Cited by 58
Self-citation
Monitoring Blood-Brain Barrier Status in a Rat Model of Glioma Receiving Therapy: Dual Injection of Low-Molecular-Weight and Macromolecular MR Contrast Media
Lemasson, B., Serduc, R., Maisin, C., Bouchet, A., Coquery, N., Robert, P., Duc, G. L., Troprés, I., Remy, C. C., & Barbier, E. (2010) · Radiology · doi:10.1148/radiol.10092343 · Cited by 58
The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review
Wu, Q., Bai, B., Tian, C., Li, D., Yu, H., Song, B., Li, B., & Chu, X. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07181-3 · Cited by 60
Brain Tumors
Brandão, L. A., Shiroishi, M. S., & Law, M. (2013) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2013.02.003 · Cited by 57
Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers
Lindauer, A., Gion, P. D., Kanefendt, F., Tomalik‐Scharte, D., Kinzig, M., Rodamer, M., Dodos, F., Sörgel, F., Fuhr, U., & Jaehde, U. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.20 · Cited by 57
Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC
Lewintre, E. J., Sanmartín, E., Sirera, R., Blasco, A., Sánchez, J. J., Tarón, M., Rosell, R., & Camps, C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.016 · Cited by 57
Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade
Secondini, C., Coquoz, O., Spagnuolo, L., Spinetti, T., Peyvandi, S., Ciarloni, L., Botta, F., Bourquin, C., & Rüegg, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1316437 · Cited by 58
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
Schneider, B. P., Gray, R. J., Radovich, M., Shen, F., Vance, G. H., Li, L., Jiang, G., Miller, K. D., Gralow, J. R., Dickler, M. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3029 · Cited by 56
Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors?
O’Connor, J. P. B., & Jayson, G. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1501 · Cited by 54
A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma
Orecchia, P., Conte, R., Balza, E., Petretto, A., Mauri, P., Mingari, M. C., & Carnemolla, B. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.019 · Cited by 54
Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer
Chambers, S. K., Clouser, M. C., Baker, A. F., Roe, D. J., Cui, H., BREWER, M. A., Hatch, K. D., Gordon, M. S., Janicek, M. F., Isaacs, J. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0974 · Cited by 54
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Somlo, G., Atzori, F., Strauss, L. C., Geese, W. J., Specht, J. M., Gradishar, W. J., Rybicki, A., Sy, O., Vahdat, L. T., & Cortés, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0652 · Cited by 53
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
Shang, B., Cao, Z., & Zhou, Q. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0176-8 · Cited by 53
Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer
Salgia, R. (2011) · Cancer · doi:10.1002/cncr.25935 · Cited by 52
Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium
Nadella, V., Singh, S. K., Jain, A., Jain, M., Vásquez, K. M., Sharma, A. K., Tanwar, P., Rath, G. K., & Prakash, H. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22879 · Cited by 52
Natural products targeting tumour angiogenesis
Lu, X., Friedrich, L. J., & Efferth, T. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16232 · Cited by 56
Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
Ahluwalia, M. S., & Gladson, C. L. (2010) · Journal of Oncology · doi:10.1155/2010/689018 · Cited by 55
Circulating endothelial cells as biomarkers in clinical oncology
Mancuso, P., & Bertolini, F. (2010) · Microvascular Research · doi:10.1016/j.mvr.2010.02.007 · Cited by 51
Texture Analysis of Non–Contrast-Enhanced Computed Tomography for Assessing Angiogenesis and Survival of Soft Tissue Sarcoma
Hayano, K., Tian, F., Kambadakone, A. R., Yoon, S. S., Duda, D. G., Ganeshan, B., & Sahani, D. V. (2015) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000239 · Cited by 51
Self-citation
Modelling the transport of fluid through heterogeneous, whole tumours in silico
Sweeney, P. W., d’Esposito, A., Walker‐Samuel, S., & Shipley, R. J. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006751 · Cited by 51
Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?
Duda, D. G., Ancukiewicz, M., & Jain, R. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8021 · Cited by 51
Self-citation
Biomarkers of renal cell carcinoma
Ngo, T. C., Wood, C. G., & Karam, J. A. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.07.011 · Cited by 50
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
Janjigian, Y. Y., Vakiani, E., Ku, G. Y., Herrera, J., Tang, L. H., Bouvier, N., Viale, A. J., Socci, N. D., Capanu, M., Berger, M. F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134731 · Cited by 50
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
Carbone, C., Piro, G., Simionato, F., Ligorio, F., Cremolini, C., Loupakis, F., Alì, G., Rossini, D., Merz, V., Santoro, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3153 · Cited by 50
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors
Nault, J., Pigneur, F., Charles‐Nelson, A., Costentin, C. E., Tselikas, L., Katsahian, S., Diao, G., Laurent, A., Mallat, A., Duvoux, C., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.07.001 · Cited by 51
Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment
Chen, C., Cheng, C.-T., Yuan, Y., Zhai, J., Arif, M., Fong, L. W. R., Wu, R., & Ann, D. K. (2015) · Oncotarget · doi:10.18632/oncotarget.3827 · Cited by 52
Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology
Benazzi, C., Al-Dissi, A. N., Chau, C. H., Figg, W. D., Sarli, G., Oliveira, J., & Gärtner, F. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/919570 · Cited by 53
Targeting HIBCH to reprogram valine metabolism for the treatment of colorectal cancer
Shan, Y., Gao, Y., Jin, W., Fan, M., Wang, Y., Gu, Y., Shan, C., Sun, L., Li, X., Yu, B., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1832-6 · Cited by 47
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
Lamb, L. S., Sim, H., & McCormack, A. I. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.576027 · Cited by 48
Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
Meyerhardt, J. A., Ancukiewicz, M., Abrams, T. A., Schrag, D., Enzinger, P. C., Chan, J. A.-W., Kulke, M. H., Wolpin, B. M., Goldstein, M., Blaszkowsky, L. S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038231 · Cited by 48
Self-citation
In Vivo Imaging of Tumor Physiological, Metabolic, and Redox Changes in Response to the Anti-Angiogenic Agent Sunitinib: Longitudinal Assessment to Identify Transient Vascular Renormalization
Matsumoto, S., Saito, K., Takakusagi, Y., Matsuo, M., Munasinghe, J., Morris, H. D., Lizak, M. J., Merkle, H., Yasukawa, K., Devasahayam, N., et al. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5725 · Cited by 46
Hypoxia control to normalize pathologic angiogenesis: Potential role for endothelial precursor cells and miRNAs regulation
Collet, G., Skrzypek, K., Grillon, C., Matejuk, A., Hafny‐Rahbi, B. E., Lamerant‐Fayel, N., & Kiéda, C. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.03.001 · Cited by 45
Correlation of Circulating Angiogenic Factors with Circulating Tumor Cells and Disease Recurrence in Patients Undergoing Curative Resection for Colorectal Liver Metastases
Rahbari, N. N., Reißfelder, C., Mühlbayer, M., Weidmann, K., Kahlert, C., Büchler, M. W., Weitz, J., & Koch, M. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1761-9 · Cited by 47
Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer
Rahbari, N. N., Schmidt, T., Falk, C. S., Hinz, U., Herber, M., Bork, U., Büchler, M. W., Weitz, J., & Koch, M. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-286 · Cited by 47
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
Schneider, B. P., Shen, F., & Miller, K. D. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70275-9 · Cited by 46
Inorganic nanomaterials for tumor angiogenesis imaging
Liu, Z., & Peng, R. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1452-y · Cited by 46
CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance
Ma, S., Mangala, L. S., Hu, W. S., Bayaktar, E., Yokoi, A., Hu, W., Pradeep, S., Lee, S., Piehowski, P., Villar‐Prados, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109549 · Cited by 48
Controversies and challenges regarding the impact of radiation therapy on survival
Chargari, C., Soria, J., & Deutsch, É. (2012) · Annals of Oncology · doi:10.1093/annonc/mds217 · Cited by 51
The role of targeted therapy and biomarkers in breast cancer treatment
Stopeck, A., Brown-Glaberman, U. A., Wong, H. Y., Park, B. H., Barnato, S. E., Gradishar, W. J., Hudis, C. A., & Rugo, H. S. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9496-y · Cited by 46
Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation
Takano, S. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-011-0077-6 · Cited by 47
Metronomic Scheduling of Anticancer Treatment: The Next Generation of Multitarget Therapy?
André, N., Padovani, L., & Pasquier, E. (2011) · Future Oncology · doi:10.2217/fon.11.11 · Cited by 44
Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases
Merz, M., Komljenovic, D., Zwick, S., Semmler, W., & Bäuerle, T. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.08.019 · Cited by 45
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
Swanton, C., Larkin, J., Gerlinger, M., Eklund, A. C., Howell, M. T., Stamp, G., Downward, J., Gore, M. E., Futreal, P. A., Escudier, B. J., et al. (2010) · Genome Medicine · doi:10.1186/gm174 · Cited by 45
Fit-for-purpose biomarker method validation in anticancer drug development
Cummings, J., Ward, T. H., & Dive, C. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.07.006 · Cited by 44

Authors: Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G.
Affiliations: Harvard University (US)
Duke Medical Center (US)
Corresponding author: Jain, Rakesh K.
ORCID: Duda, Dan G.
Willett, Christopher G.
Zhu, Andrew X.
Batchelor, Tracy T.
Sorensen, A. Gregory
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2009-06
Volume: 6
Issue: 6
Pages: 327-338
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2009.63
PMC: PMC3057433
OpenAlex: W1993016882
Cited by: 572
References: 83
Citations by year: 2026: 10 · 2025: 14 · 2024: 9 · 2023: 15 · 2022: 11 · 2021: 19 · 2020: 26 · 2019: 17 · 2018: 25 · 2017: 33 · 2016: 35 · 2015: 38 · 2014: 44 · 2013: 57 · 2012: 67
FWCI: 5.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA115767, R01CA57683, R01 CA 85140, R21CA117079, R01CA085140, R01CA057683, R21-CA 99237, P01CA080124, R21CA099237, R01CA126642, K24CA125440, R01CA129371, P01-CA-80124)
National Center for Research Resources (P41-RR-14075, M01RR001066, P41RR014075, M01-RR01066)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: anti-angiogenic therapy, biomarkers, treatment response, drug resistance, patient selection, VEGF polymorphisms, type IV collagen, pharmacodynamic biomarkers, imaging biomarkers, Ktrans, placental growth factor, stromal cell-derived factor-1α, interleukin-6, tumor stroma
MeSH terms: Humans, Neoplasms, Neovascularization, Pathologic, Biomarkers, Tumor, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biomarkers of response and resistance to antiangiogenic therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks